VitriVax awarded $9.9M grant to enable scaling up of clinical manufacturing
Business Wire—VitriVax Inc., a ³Ô¹ÏÍø of Colorado Boulder vaccine formulation technology spinout, today announced it has been awarded a two-year, $9.9 million grant from the Gates Foundation. The funding will support the scale-up of VitriVax’s Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology, enabling Phase 1-ready GMP manufacturing and advancing the platform to prepare for Phase 1 clinical trials.
The ³Ô¹ÏÍø of Colorado Connection
VitriVax is a biotechnology company working to eliminate barriers to global vaccination, and has developed a novel stabilization and delivery platform for vaccines and therapeutics based on research in the laboratories of (CU Boulder Molecular, Cellular & Developmental Biology) and Ìýat CU Boulder (CU Boulder Chemical and Biological Engineering).
The Newsroom
For marketing and communication inquiries or news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit .